Advertisement

Topics

CC Chemokine Receptor Type 5 CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5 Pipeline Review, H2 2018 [Report Updated: 14082018] Prices from USD $3500

06:54 EDT 12 Oct 2018 | BioPortfolio Reports

CC Chemokine Receptor Type 5 CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5 Pipeline Review, H2 2018


Summary


According to the recently published report 'CC Chemokine Receptor Type 5 Pipeline Review, H2 2018'; CC Chemokine Receptor Type 5 CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5 pipeline Target constitutes close to 10 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.


CC Chemokine Receptor Type 5 CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5 CC chemokine receptor type 5 CCR5 also known as CD195, is a surface protein located on the plasma membrane of white blood cells and is encoded by CCR5 gene. This receptor binds and responds to a variety of chemokines CCL3, CCL4, CCL5, CCL3L1. This protein is expressed by T cells and macrophages, and is known to be an important coreceptor for macrophagetropic virus, including HIV, to enter host cells. It plays a role in granulocyte lineage proliferation and differentiation.


The report 'CC Chemokine Receptor Type 5 Pipeline Review, H2 2018' outlays comprehensive information on the CC Chemokine Receptor Type 5 CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.


It also reviews key players involved in CC Chemokine Receptor Type 5 CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 1 and 3 respectively.


Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Infectious Disease, Oncology, Gastrointestinal and Immunology which include indications Human Immunodeficiency Virus HIV Infections AIDS, Graft Versus Host Disease GVHD, Liver Fibrosis, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, NonAlcoholic Steatohepatitis NASH, Pancreatic Ductal Adenocarcinoma and Primary Sclerosing Cholangitis.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for CC Chemokine Receptor Type 5 CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5

The report reviews CC Chemokine Receptor Type 5 CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in CC Chemokine Receptor Type 5 CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5 targeted therapeutics and enlists all their major and minor projects

The report assesses CC Chemokine Receptor Type 5 CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to CC Chemokine Receptor Type 5 CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for CC Chemokine Receptor Type 5 CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding CC Chemokine Receptor Type 5 CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: CC Chemokine Receptor Type 5 CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5 Pipeline Review, H2 2018 [Report Updated: 14082018] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "CC Chemokine Receptor Type 5 CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5 Pipeline Review, H2 2018 [Report Updated: 14082018] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cytokine
Cytokines include chemokines, lymphokines, and monokines. Cells of the immune system communicate with one another by releasing and responding to chemical messengers called cytokines. These proteins are secreted by immune cells and act on other cells to...

AIDS and HIV
AIDS; Acquired Immune Deficiency Syndrome. HIV; Human Immunodeficiency Virus HIV infection causes AIDS. HIV infection also causes the production of anti-HIV antibodies, which forms the test for HIV in patients. People who have the HIV antibodies are ...